Tania F. de Koning‐Ward

This paper identifies MMV006833 as an inhibitor of PfSTART1 in P. falciparum but shows it is ineffective against P. berghei due to structural differences and other factors.

This study identifies MMV687794 as an inhibitor of Plasmodium falciparum RBC invasion by targeting PfSLIRP, a rhoptry protein involved in lipid metabolism and vacuole formation.

This study identifies PfK13 mutations as drivers of artemisinin resistance by enhancing antioxidant defenses, which can be counteracted by sulforaphane.

This study identifies M-512 as an agonist of PfROM8 and PfCSC1, which are essential for Plasmodium falciparum growth, and shows that their dysregulation reduces parasite viability.

The paper identifies aryl amino acetamides that inhibit Plasmodium falciparum ring development by targeting PfSTART1, a lipid transfer protein, and shows these inhibitors block parasite transmission.

This paper identifies MMV1557817 as a dual aminopeptidase inhibitor effective against multiple Plasmodium species and highlights its potential as a multi-target antimalarial drug.

This study identifies MMV020291 as a compound that targets actin-1/profilin dynamics in Plasmodium falciparum, inhibiting red blood cell invasion and apicoplast segregation.